[Clinical evaluation of azithromycin for respiratory infectious diseases].
Azithromycin(AZM), an azalide macrolide with a 15-membered ring, is superior in cell/tissue penetration. Sustained pulmonary tissue concentrations are maintained which are higher than various MICs for major respiratory pathogens. Much research and clinical investigation has been done to evaluate the clinical efficacy of azithromycin abroad. In Japan, an optimal dose-finding pneumonia study was started in January, 1993, and a controlled comparative pneumonia study with clarithromycin was started in December of the same year. Patient compliance was excellent with the 3-day once daily regimen of AZM(500 mg). Azithromycin has been demonstrated to be highly clinically useful based on high efficacy (including the elderly population) and an established safety profile.
Oizumi
K
K
First Department of Internal Medicine, Kurume University School of Medicine.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D017963:Azithromycin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D006801:Humans; D010349:Patient Compliance; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D017963:Azithromycin